Pilot CBD Trial Signals Lower Opioid Use After Knee Surgery; Primary Test Nonsignificant
A triple-blind 36-person pilot compared placebo with 400 mg and 800 mg perioperative CBD. The 400 mg opioid reduction was nonsignificant in the primary comparison and significant only post hoc. The 800 mg arm lacked benefit and had more adverse-event burden, so efficacy is not established.
For the full article, please visit the original source link below. CannabisInsight curates and summarizes key news from the global cannabis and hemp industry.
Source
sciencedirect.com
CannabisInsight selects and summarizes news from external sources. Copyright in the original articles remains with the respective publishers or institutions. Follow the source links for full reporting and context.
Original Link
https://www.sciencedirect.com/science/article/abs/pii/S1526590026002956